PROKIDNEY CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.575 USD | +1.85% |
|
-7.39% | +97.19% |
| May. 10 | ProKidney Q1 Loss Unchanged From Year Earlier | MT |
| May. 10 | ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 224M |
|---|---|---|---|---|---|
| Net income 2024 * | -146M | Net income 2025 * | -43M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 193M | Net cash position 2025 * | 310M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.75
x | P/E ratio 2025 * |
-4.9
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 day | -3.04% | ||
| 1 week | -7.39% | ||
| Current month | +69.98% | ||
| 1 month | +38.74% | ||
| 3 months | +132.45% | ||
| 6 months | +96.09% | ||
| Current year | +97.19% |
1 week
3.42
4.44
1 month
2.034.44
Current year
1.184.44
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 23-07-16 |
James Coulston
DFI | Director of Finance/CFO | 48 | 21-12-31 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 21-12-31 |
Brian Pereira
BRD | Director/Board Member | 65 | 21-12-31 |
John Maraganore
BRD | Director/Board Member | 60 | 22-08-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 3.51 | -3.04% | 811 142 |
| 24-05-22 | 3.62 | -2.16% | 551,461 |
| 24-05-21 | 3.7 | -4.64% | 649,828 |
| 24-05-20 | 3.88 | -4.32% | 1,199,247 |
| 24-05-17 | 4.055 | +6.99% | 546,776 |
End-of-day quote Nasdaq, May 22, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
2024-05-25
- ERA Congress
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.51
USD
Average target price
4.4
USD
Spread / Average Target
+25.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +97.19% | 224M | |
| +64.92% | 62.86B | |
| -1.85% | 41.38B | |
| +45.32% | 40.38B | |
| -8.93% | 27.64B | |
| +13.05% | 26.46B | |
| -21.96% | 18.9B | |
| +4.21% | 12.67B | |
| +25.74% | 12.27B | |
| +27.42% | 12.07B |
- Stock Market
- Equities
- PROK Stock
